Urine Proteomics Service

Urine proteomics refers to the scientific field that conducts comprehensive analysis and research of proteins in urine using high-throughput technologies. As a non-invasive biological sample, urine offers unique advantages such as easy acquisition, ample sample volume, and the ability to reflect the body’s overall physiological and pathological states. Urine contains a vast array of proteins derived from the kidneys, urinary system, and secretions and metabolic activities of various organs throughout the body. Therefore, urine proteomics not only reveals the types and abundances of proteins present in urine but also reflects the individual’s health status and potential diseases. Conducting urine proteomics analysis can help scientists and clinicians discover new biomarkers for early disease diagnosis, prognostic evaluation, and monitoring treatment efficacy. Additionally, due to its non-invasive nature and high sensitivity, urine proteomics is particularly suitable for long-term health monitoring and large-scale epidemiological studies.

 

Urine proteomics effectively addresses numerous issues present in traditional diagnostic methods. Firstly, it provides a simple and cost-effective way to obtain biological samples, avoiding the discomfort and risks associated with invasive examinations, which is especially beneficial for patients requiring frequent monitoring of chronic diseases. Secondly, urine proteomics, through high-sensitivity mass spectrometry technology, can detect low-abundance biomarkers, enhancing the accuracy of early disease detection. For instance, in studies of kidney diseases, diabetes, and various cancers, urine proteomics has demonstrated significant potential in discovering specific biomarkers and understanding disease mechanisms. Moreover, urine proteomics can be utilized in drug development and personalized medicine by analyzing protein changes in patients’ urine to optimize treatment plans, improve efficacy, and reduce side effects. With continuous advancements in technology and data analysis methods, urine proteomics is set to play an increasingly important role in precision medicine and personalized healthcare, providing more reliable and comprehensive support for public health and clinical diagnostics.

 

Service at MtoZ Biolabs

MtoZ Biolabs, an integrated chromatography and mass spectrometry (MS) services provider, provides advanced proteomics, metabolomics, and biopharmaceutical analysis services to researchers in biochemistry, biotechnology, and biopharmaceutical fields. Our ultimate aim is to provide more rapid, high-throughput, and cost-effective analysis, with exceptional data quality and minimal sample consumption, MtoZ Biolabs offers cutting-edge urine proteomics services based on advanced high-sensitivity mass spectrometry, delivering accurate and reliable results. MtoZ Biolabs maintains strict quality control throughout the process and offer personalized solutions tailored to specific research needs and ensure fast, efficient service. Trust MtoZ Biolabs for precise and comprehensive urine proteomics analysis.

 

Analysis Workflow

 



Joshi, N. et al. Clin Proteomics. 2024.

Figure 1. The workflow of Urine Proteomics

 

Service Advantages

1. High-Sensitivity Mass Spectrometry Analysis: Equipped with state-of-the-art high-sensitivity mass spectrometers, MtoZBiolabs is capable of detecting low-abundance proteins in urine. Even within the complex background of urine samples, MtoZ Biolabs accurately identifies target proteins, ensuring comprehensive urine proteomics analysis.

 

2. Advanced Sample Preparation Techniques: MtoZ Biolabs employs advanced desalting and protein enrichment methods to effectively remove interfering substances such as urea and salts from urine samples. This significantly reduces the complexity of the proteome, enhancing the accuracy and reliability of protein identification.

 

3. One-Time-Charge: Our pricing is transparent, no hidden fees or additional costs.

 

4. High-Data-Quality: Deep data coverage with strict data quality control. AI-powered bioinformatics platform integrates all urine proteomics data, providing clients with a comprehensive data report.

 

Applications

1. Identification of Disease Biomarker

Early detection of gastric cancer (GC) remains challenging. Researchers aimed to examine urine proteomics and identify protein biomarkers that predict the progression of gastric lesions and the risk of GC. Initially, a case-control study was designed, encompassing subjects with GC and various stages of gastric lesions. Participants were aged 40-69 years and had no prior diagnosis of kidney or urinary system diseases. A total of 255 subjects were recruited, including 123 in the discovery phase from Linqu, China, a high-risk area for GC, and 132 in the validation phase from Linqu and Beijing. Additionally, a prospective study was designed involving 60 subjects with gastric lesions, who were followed for 297-857 days. Researchers identified 43 differentially expressed urine proteins in subjects with GC and mild or advanced gastric lesions. The levels of ANXA11, CDC42, NAPA, and SLC25A4 in urine were positively correlated with the risk of gastric lesion progression. Except for SLC25A4, the expression of these three proteins was also higher in GC tissues compared to non-GC tissues. The combination of these four proteins demonstrated excellent performance in predicting the progression of gastric lesions (AUC [95% CI]: 0.92 [0.83–1.00]) and the risk of GC (AUC [95% CI]: 0.81 [0.73–0.89] and 0.84 [0.77–0.92] for GC versus mild or advanced gastric lesions, respectively). This study revealed distinct urine proteomic profiles and a set of proteins that may predict the progression of gastric lesions and the risk of GC. These non-invasive biomarkers may have translational significance for identifying high-risk populations for GC and facilitating its early detection.

 



Fan, H. et al. EBioMedicine. 2022.

Figure 2. The Schematic Diagram of Study Design and Workflow

 

2. Monitoring the Disease Course

Long-term monitoring of bladder cancer requires invasive and expensive procedures. There is a need to use readily available biological samples, such as urine, to adopt less invasive methods. In this study, researchers demonstrated a longitudinal analysis method of the urine proteome to monitor the disease course in bladder cancer patients. They compared the urine proteomes of patients with recurrence and/or progression (n = 13) to those of patients without recurrence and/or progression (n = 17). Differentially expressed proteins in various pathways associated with cancer characteristics were identified. Using the Differential Personal Pathway Index (dPPi) calculations, researchers determined changes in these pathways during the disease course, which may indicate the necessity of disease progression and medical intervention. Seven signature pathways were used to develop the dPPi. Researchers demonstrated that by combining urine proteomics analysis with dPPi calculations, they could successfully longitudinally monitor the disease course of bladder cancer patients over a period of 62 months. The dPPi utilizes information contained in the patients' urine proteomes to reflect the individual disease course of bladder cancer and helps optimize the use of more invasive examination procedures, such as cystoscopy.

 



Carvalho, LB. et al. Commun Med (Lond). 2023.

Figure 3. Selection of Pathway Hallmarks of Cancer

 

Deliverables

1. Comprehensive Experimental Details

2. Materials, Instruments, and Methods

3. Relevant Liquid Chromatography and Mass Spectrometry Parameters

4. The Detailed Information of Urine Proteomics

5. Mass Spectrometry Image

6. Raw Data